In an editorial the NY Times is taking issue with the discarding “of unsuitable kidneys”. The point that they
raise is that if the distribution system was more efficient and fairer perhaps
half of over 2600 discarded kidneys might have been used. Kevin Sack in a separate article in the Times reviews
a new system proposed by a UNOS committee: “the top 20 percent of kidneys would be matched to the candidates
expected to survive the longest, placing older patients at a disadvantage. But
the remaining 80 percent would still be allocated primarily by time spent on
the wait list.”
The UNOS concept
document is downloadable and
provides insights into the current system and the proposed new system. UNOS is
looking for feedback preferably by email kidneypolicy@unos.org.
http://ajkdblog.org/2012/09/25/proposal-to-change-the-allocation-of-deceased-donor-kidneys-smart-allocation-or-discrimination/
ReplyDeleteI'm very thankful to the author for posting such an amazing post..!
ReplyDeleteessay guarantee
Bristol-Myers Squibb drug brivanib test failure
ReplyDeleteU.S. Bristol-Myers Squibb pharmaceutical company said late-stage clinical trials of the experimental drug brivanib did not achieve the desired test objectives, ended in failure.
It is reported that, in clinical trials, researchers will brivanib drug Nexavar (Nexavar) efficacy, but brivanib drug efficacy enemy Nexavar (Nexavar). It is reported that Nexavar drug is jointly developed by Bayer Pharmaceutical Group with Onyx Pharmaceuticals, Inc..
Bristol-Myers Squibb pharmaceutical company brivanib drugs are oral drugs, patients receiving the drug treatment, need to be taken once a day. It is reported that the drugs belonging to the can at the same time inhibit fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) signal transduction selective dual inhibitors, the drug can also inhibit the generation FGFR tyrosine kinase, a tyrosine kinase can cause various types of cancer lesions.
Bristol-Myers Squibb pharmaceutical company apprentice, the company will continue to expand a series of clinical trials of the drug, mainly to review the level of efficacy of the drug in the treatment of kidney cancer and other tumor diseases.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
TG 100572
Bosutinib
Nilotinib
Dasatinib
Saracatinib
Fingolimod
Bafetinib
R406 free base
R406
R788(prodrug of R406)